Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 6
Submit an article Journal homepage
89
Views
5
CrossRef citations to date
0
Altmetric
Drug Evaluation

Zoledronic acid for cancer therapy-induced and postmenopausal bone loss

Adam M Brufsky UPMC Cancer Center Magee-Womens Hospital, Suite 4628, 300 Halket Street, Pittsburgh, PA 15213, USA +1 412 641 6500; +1 412 641 2296; [email protected]
, MD PhD
Pages 1013-1028 | Published online: 01 Apr 2008

Bibliography

  • Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-8
  • Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006;28:1551-73
  • Dawson-Hughes B, Bonner FJ Jr, Gold DT, et al. National Osteoporosis Foundation Web Site. Physician's guide to prevention and treatment of osteoporosis. Available from: www.nof.org/physguide/inside_cover.htm [Last accessed 10 October 2007]
  • Fogelman I, Blake GM, Blamey R, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14:1001-6
  • Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219-22
  • Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole; ZO-FAST study results. Cancer 2008;112:1001-10
  • Gandhi MK, Lekamwasam S, Inman I, et al. Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 2003;121:462-8
  • Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 2004;31:331-52
  • Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215-23
  • Devogelaer JP, Goemaere S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006;17:8-19
  • Slemenda CW, Christian JC, Reed T, et al. Long-term bone loss in men: effects of genetic and environmental factors. Ann Intern Med 1992;117:286-91
  • Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid effectively prevents cancer treatment–induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-8
  • Asmar L, Negron AG, Stokoe CT, et al. The effect of tamoxifen or exemestane on bone mineral density after 2 years of adjuvant treatment of postmenopausal women with early breast cancer [abstract 2102]. 29th San Antonio Breast Cancer Symposium; 2006 Dec 14 – 17; San Antonio, TX
  • Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole–induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-36
  • Brufsky A, Lund K, Cobb P, et al. Twenty-four month follow-up of the effect of zoledronic acid on aromatase inhibitor–associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole [abstract 5060]. 29th San Antonio Breast Cancer Symposium; 2006 Dec 14 – 17; San Antonio, TX
  • Brufsky A, Bundred N, Coleman R, et al. An integrated analysis of zoledronic acid for prevention of aromatase inhibitor–associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole [abstract 107]. 29th San Antonio Breast Cancer Symposium; 2006 Dec 14 – 17; San Antonio, TX
  • Coleman RE, Banks LM, Hall E, et al. Intergroup Exemestane Study: 1 year results of the bone sub-protocol [abstract 401]. 27th San Antonio Breast Cancer Symposium; 2004 Dec 8 – 11; San Antonio, TX
  • Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051-58
  • Geisler J, Lønning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006;42:2968-75
  • Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 2007;40:205-10
  • Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629-35
  • Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71
  • Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:2361-7
  • Casey R. Zoledronic acid reduces bone loss in men with prostate cancer receiving goserelin: 12-month results [abstract 198]. American Society of Clinical Oncology Prostate Cancer Symposium; 2007 Feb 22 – 24; Orlando, FL
  • Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000;163:181-6
  • Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005;90:6410-7
  • Higano C, Shields A, Wood N, et al. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004;64:1182-6
  • Israeli RS, Rosenberg S, Saltzstein D, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen-deprivation therapy. Clin Genitourin Cancer 2007;5:271-7
  • Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007;25:1038-42
  • Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002;87:3656-61
  • Ryan CW, Huo D, Demers LM, et al.; the Zometa US05 Investigators. Zoledronic acid initiated during the first year of androgen-deprivation therapy increases bone mineral density in patients with prostate cancer patients. J Urol 2006;176:972-8
  • Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55
  • Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12
  • Tauchmanovà L, Ricci P, Serio B, et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2005;90:627-34
  • Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006;20:1029-39
  • Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92
  • Howell A, Cuzick J, Baum M, et al.; for the ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2
  • Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119-27
  • Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897-903
  • Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64
  • D'Souza AB, Grigg AP, Szer J, Ebeling PR. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Intern Med J 2006;36:600-3
  • Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 2006;63:419-30
  • Riggs BL, Khosla S, Melton J III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302
  • Vehmanan L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006;24:675-80
  • Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-9
  • Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36
  • Anonymous. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003;921:1-164
  • Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006;24:5305-12
  • Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
  • Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61
  • McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41:122-8
  • Hodgson SF, Watts NB. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Prevention and Treatment of Postmenopausal Osteoporosis: 2001 Edition, with selected updates for 2003. Endocr Pract 2003;9:544-64
  • Wei GS, Jackson JL, O'Malley PG. Postmenopausal osteoporosis risk management in primary care: how well does it adhere to national practice guidelines? J Am Womens Med Assoc 2003;58:99-104
  • Ettinger B, Harris ST, Kendler D, et al. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. J N Am Menopause Soc 2006;13:340-67
  • Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
  • Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52
  • McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
  • Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
  • Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
  • Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
  • Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922-8
  • Perry CM, Figgitt DP. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 2004;64:1197-211
  • Green JR. Preclinical pharmacology of zoledronic acid. Semin Oncol 2002;29(Suppl 21):3-11
  • Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007
  • Zometa [package insert]. Horsham, UK: Novartis Europharm Limited; 2006
  • Reclast [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007
  • Aclasta [package insert]. Dorval, Quebec: Novartis Pharmaceuticals Canada, Inc.; 2007
  • Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907
  • Brufsky A, Bosserman L, Caradonna R, et al. The effect of zoledronic acid on aromatase inhibitor–associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up [abstract 27]. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13 – 16; San Antonio, TX
  • De Boer R, Editmann H, Lluch A, et al. Zoledronic acid in the prevention of aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24 month BMD results [abstract 501]. 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13 – 16; San Antonio, TX
  • Alonso B, Aleman R, Rodriguez L, et al. Bone mineral density in women with non-metastatic breast cancer: effect of intravenous bisphosphonates given before adjuvant therapies [abstract 11038]. J Clin Oncol 2007;25(18S Pt I):597s
  • Brown JE, Ellis SP, Lester JE, et al. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007;13:5406-10
  • Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809
  • Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008;23:6-16
  • Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14
  • Early communication of an ongoing safety review bisphosphonates: alendronate (fosamax, fosamax plus d), etidronate (didronel), ibandronate (boniva), pamidronate (aredia), risedronate (actonel, actonel w/calcium), tiludronate (skelid), and zoledronic acid (reclast, zometa): US Food and Drug Administration Center for Drug Evaluation and Research, 2007. Available from: http://www.fda.gov/cder/drug/early_comm/bisphosphonates.htm [Last accessed 6 December 2007]
  • Center JR, Nguyen TV, Schneider R, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82
  • Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57
  • The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (version 1.2008). ©2008 National Comprehensive Cancer Network, Inc. Available from: http://www.nccn.org [Last accessed 4 March 2008]
  • The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (version 2.2008). ©2008 National Comprehensive Cancer Network, Inc. Available from: http://www.nccn.org [Last accessed 4 March 2008]
  • Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005;22:195-201

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.